ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
Morepen Laboratories held its 41st Annual General Meeting on September 26, 2026, to conduct routine business, including dividend declaration and approval of director appointments.
Morepen Laboratories has been assigned an 'Adequate' ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited based on publicly disclosed information.
Morepen Laboratories successfully completed the first phase of its manufacturing capacity expansion. Installed reactor capacity for API and CDMO operations increased from 535 KL to 614 KL.
Morepen Laboratories dispatched a notice to shareholders without registered emails providing the Annual Report 2025-26 weblink. The company proposed a final dividend of ₹0.20 per share.
Morepen Laboratories has scheduled its 41st Annual General Meeting for September 26, 2026. The board has proposed a final dividend of ₹0.20 per equity share.
Morepen Laboratories secured a multi-year CDMO mandate worth approximately ₹825 Crore from a global pharmaceutical firm. This represents one of the largest single mandates in the company's history.
Morepen Laboratories has invested Rs. 20 Crore via a rights issue in its wholly-owned subsidiary, Morepen RX Limited, to strengthen its capital base.
Morepen Laboratories' board recommended a final dividend of Rs. 0.20 per equity share for FY 2025-26. The record date for the dividend is September 19, 2026.
Morepen Laboratories Limited has re-appointed Sushil Suri as Executive Director for a 36-month term, effective October 20, 2026. The Board approved this management change.
Morepen Laboratories' Monitoring Agency Report for Q1 FY27 confirms usage of QIP proceeds. The company faces a GST show-cause notice of ₹117.94 crore.
Morepen Laboratories reported record Q1 FY27 revenue of Rs. 575.31 Crore, up 34% YoY. Net profit surged 394% to Rs. 56.35 Crore following CDMO commercialization.
Morepen delivers explosive Q1'FY27 growth with 207% EBITDA jump, driven by the first commercial CDMO dispatches and operational leverage. The 'Morepen 2.0' strategy shifts focus from commodity APIs to high-margin innovation-led manufacturing.
Morepen Laboratories Ltd reported revenue from operations of ₹570.1 Cr (+34.1% YoY) and net profit of ₹56.3 Cr (+393.9% YoY) for Q1 FY27.
Morepen Laboratories has scheduled a board meeting for August 4, 2026, to approve the financial results for the quarter ended June 30, 2026.
Morepen Laboratories' wholly owned subsidiary, Morepen Labs - FZCO, changed its name to Morepen Labs FZE following migration from IFZA to JAFZA, Dubai.
Morepen Laboratories started commercial supplies under an ₹825 Crore CDMO mandate. The first dispatch of ₹50 Crore was completed in Q1FY2026-27.
Mr. Sanjay Suri is elevated from Whole-time Director to Managing Director. The appointment is effective from 1st July 2026.
Morepen Laboratories clarified that the recent trading volume spurt is market-driven. No undisclosed price-sensitive events or pending announcements exist, ensuring market transparency.
Morepen Labs reported Q4 FY26 revenue of ₹472 Cr, up 22% YoY, while shifting focus toward long-term CDMO contracts and high-margin medical devices.
Morepen Labs reported a 69% YoY net profit rise to ₹20 Crore for Q4 FY26. Strong growth in medical devices and CDMO execution support long-term visibility.
Morepen Laboratories recommended a final dividend of Rs. 0.20 per equity share for FY 2025-26. The record date will be announced in due course.
Morepen Laboratories revised the 'Appointed Date' for its internal business transfer to subsidiary Morepen Medipath to April 1, 2026. The delay allows time for statutory and regulatory approvals.
Morepen Laboratories re-appointed M/s. Vijender Sharma & Co. as Cost Auditors for a 12-month term. The decision ensures continued regulatory compliance for the company.
Morepen Laboratories Ltd reported revenue from operations of ₹484.7 Cr (+4.0% YoY) and net profit of ₹15.7 Cr (-22.7% YoY) for Q4 FY26.
Morepen Laboratories reported audited FY26 results and recommended a Rs. 0.20 per share final dividend. The board also revised the Medical Devices business transfer date.
Morepen Laboratories rescheduled its Board meeting to May 26, 2026. The meeting will now include consideration of a final dividend for the 2026 financial year.
Morepen Laboratories transferred a 9% stake in subsidiary Morepen Medipath to its Medical Devices head. The subsidiary remains consolidated despite the parent's stake reducing to 51%.
Morepen Laboratories transferred a 9% stake in its subsidiary, MML, to Mr. Anubhav Suri. The company retains control with a 51% majority shareholding.
Morepen Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 2026. The report notes unresolved observations regarding share cancellation and listing alignment.
Morepen Laboratories Ltd submitted its Monitoring Agency Report for the quarter ended March 31, 2026. The report details the utilization of ₹200 Crore raised via QIP, including ₹109.23 Crore deployed for modernization and ₹66.29 Crore for working capital. The company extended the utilization timeline for medical device development at Baddi to March 2027.